FLXN Flexion Therapeutics Inc.

10.22
-0.03  -0%
Previous Close 10.25
Open 10.26
Price To Book 3.52
Market Cap 388283483
Shares 37,992,513
Volume 502,896
Short Ratio
Av. Daily Volume 640,442

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation of enrolment announced January 2, 2019. To be completed in 2020.
Zilretta
Osteoarthritis of the hip
Approval announced October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes
PDUFA date for sNDA filing October 14, 2019.
Zilretta - FX006 repeat
Osteoarthritis of the knee
Top-line safety data due 2Q 2018.
Zilretta - FX006
Osteoarthritis of the knee

Latest News

  1. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  2. Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference
  3. Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal Drugs
  4. Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board
  5. Mutual Fund Managers Are Bullish On Stock Market Forecast — But Some Are Hedging Bets
  6. Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference
  7. Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors
  8. Edited Transcript of FLXN earnings conference call or presentation 28-Feb-19 9:30pm GMT
  9. Flexion Therapeutics Inc (FLXN) Q4 2018 Earnings Conference Call Transcript
  10. Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results
  11. Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference
  12. Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage
  13. Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  14. Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019
  15. Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy
  16. Here's Why Flexion Therapeutics Rose 29.8% in January
  17. Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12
  18. Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality — Fundamental Analysis, Key Performance Indications